-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On March 28, 2022, Axsome Therapeutics announced a definitive agreement with Jazz Pharmaceuticals to acquire Sunosi (solriamfetol)
Narcolepsy is a disabling neurological disorder in which patients cannot properly regulate the cycle of sleep and wakefulness, resulting in symptoms of drowsiness
Sunosi works through a dual mechanism to promote the patient's ability to stay awake
References:
[1] Jazz Pharmaceuticals Announces Agreement to Divest Sunosi® (solriamfetol) to Axsome Therapeutics.
[2] Axsome Therapeutics to Acquire Sunosi® from Jazz Pharmaceuticals, Expanding Axsome's Leadership in Neuroscience.
Note: The original text has been deleted